Insider Selling: Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Sells $464,287.50 in Stock

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Thomas Patrick Kelly sold 11,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $41.27, for a total transaction of $464,287.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Thomas Patrick Kelly also recently made the following trade(s):

  • On Wednesday, June 19th, Thomas Patrick Kelly sold 177 shares of Deciphera Pharmaceuticals stock. The shares were sold at an average price of $25.00, for a total transaction of $4,425.00.
  • On Monday, June 3rd, Thomas Patrick Kelly sold 2,100 shares of Deciphera Pharmaceuticals stock. The stock was sold at an average price of $25.20, for a total transaction of $52,920.00.
  • On Wednesday, May 22nd, Thomas Patrick Kelly sold 1,473 shares of Deciphera Pharmaceuticals stock. The stock was sold at an average price of $25.06, for a total transaction of $36,913.38.

Shares of DCPH opened at $36.30 on Friday. Deciphera Pharmaceuticals Inc has a 12 month low of $18.55 and a 12 month high of $42.99. The firm has a fifty day simple moving average of $23.11 and a 200 day simple moving average of $24.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Friday, August 2nd. The company reported ($0.56) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.12) by $0.56. The business had revenue of $25.00 million for the quarter, compared to analyst estimates of $20.00 million. Equities research analysts anticipate that Deciphera Pharmaceuticals Inc will post -4.29 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Dimensional Fund Advisors LP acquired a new position in Deciphera Pharmaceuticals during the fourth quarter worth $4,337,000. Geode Capital Management LLC boosted its holdings in Deciphera Pharmaceuticals by 19.4% during the fourth quarter. Geode Capital Management LLC now owns 166,904 shares of the company’s stock worth $3,503,000 after purchasing an additional 27,157 shares during the last quarter. Norges Bank acquired a new position in Deciphera Pharmaceuticals during the fourth quarter worth $6,974,000. Marshall Wace North America L.P. boosted its holdings in Deciphera Pharmaceuticals by 4,025.4% during the first quarter. Marshall Wace North America L.P. now owns 57,714 shares of the company’s stock worth $1,340,000 after purchasing an additional 56,315 shares during the last quarter. Finally, CIBC Asset Management Inc acquired a new position in Deciphera Pharmaceuticals during the first quarter worth $958,000. Institutional investors and hedge funds own 59.10% of the company’s stock.

Several equities research analysts have recently issued reports on the stock. BidaskClub raised shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. Cantor Fitzgerald increased their price objective on shares of Deciphera Pharmaceuticals from $43.00 to $55.00 and gave the stock an “overweight” rating in a research report on Wednesday. Piper Jaffray Companies increased their price objective on shares of Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, June 3rd. They noted that the move was a valuation call. Deutsche Bank assumed coverage on shares of Deciphera Pharmaceuticals in a research report on Thursday, July 18th. They set a “buy” rating and a $42.00 price objective for the company. Finally, ValuEngine downgraded shares of Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Deciphera Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $47.90.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

See Also: What is dollar cost averaging (DCA)?

Insider Buying and Selling by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.